Theophylline, a drug derived from the same chemical family as caffeine, was once the backbone of asthma treatment worldwide. Prescribed to millions from the 1930s through the 1990s, it fell out of favor as safer inhaled medications took over. Now, a growing body of research suggests that at roughly half the traditional dose, theophylline does something unexpected — it switches from a bronchodilator to an anti-inflammatory agent, working through a completely different biological mechanism. For patients with severe, treatment-resistant asthma or COPD who have exhausted other options, this old drug may still have a role to play.
But the comeback narrative is more complicated than it first appears. The largest modern clinical trial testing low-dose theophylline in COPD — the TWICS trial, involving 1,578 patients across 121 UK centers — failed to show a significant reduction in exacerbations. Current 2024–2025 guidelines from both GINA and the ERS/ATS do not recommend oral theophylline as standard therapy. And paradoxically, even for the patients who might benefit from it, ongoing supply shortages in 2025–2026 are making it harder to obtain. This article examines the science behind theophylline’s proposed second act, what the clinical evidence actually shows, where it still fits in modern treatment, and why its future remains uncertain.
Table of Contents
- Why Is Theophylline Being Reconsidered at Low Doses?
- What Does the HDAC2 Mechanism Mean for Steroid-Resistant Patients?
- The TWICS Trial and What Large-Scale Evidence Actually Shows
- Where Theophylline Still Has a Place in Clinical Practice
- Supply Shortages and the Practical Barriers to Access
- Relevance for Older Adults and Cognitive Health Considerations
- What Comes Next for Low-Dose Theophylline?
- Conclusion
- Frequently Asked Questions
Why Is Theophylline Being Reconsidered at Low Doses?
The original case for theophylline was straightforward: at plasma concentrations of 10–20 mg/L, it relaxes airway smooth muscle and opens the bronchial passages. The problem was that this therapeutic window is dangerously narrow. Push the dose slightly too high and patients face nausea, cardiac arrhythmias, and seizures. That toxicity profile, combined with the arrival of inhaled corticosteroids and long-acting beta-agonists in the 1990s, made theophylline a relic of an earlier era of pulmonary medicine. What changed the conversation was a discovery published in the Proceedings of the National Academy of Sciences in 2002. Researchers led by Kazuhiro Ito found that theophylline directly activates an enzyme called histone deacetylase-2, or HDAC2, by inhibiting a signaling molecule known as PI3K-δ.
This mechanism suppresses inflammatory genes — including GM-CSF and IL-8 — that are switched on by the transcription factor NF-κB. Critically, this anti-inflammatory pathway is entirely distinct from how corticosteroids work, which raised an intriguing possibility: theophylline might complement steroids rather than compete with them. The clinical evidence for this mechanism appeared even earlier. A 1994 study published in The Lancet by Sullivan and colleagues showed that low-dose theophylline significantly reduced eosinophils in bronchial biopsies — activated eosinophils dropped from 5.9 to 2.1, and total eosinophils fell from 16.7 to 7.6 beneath the epithelial basement membrane. These are the immune cells that drive allergic inflammation in asthma. At plasma concentrations of just 5–10 mg/L, roughly half the traditional bronchodilator dose, the drug appeared to be doing something genuinely useful without the old toxicity concerns.
What Does the HDAC2 Mechanism Mean for Steroid-Resistant Patients?
One of the most compelling aspects of low-dose theophylline is its potential to restore corticosteroid responsiveness in patients who have stopped responding to steroids. In COPD, oxidative stress and chronic inflammation progressively reduce HDAC2 activity in immune cells, particularly alveolar macrophages. When HDAC2 is impaired, corticosteroids cannot effectively silence inflammatory genes — a condition known as steroid resistance. Research published by Cosio and colleagues in a peer-reviewed study demonstrated that theophylline restores HDAC2 activity in COPD macrophages, potentially reversing this resistance and making existing steroid treatments effective again. This matters because steroid resistance is one of the most frustrating clinical problems in severe asthma and COPD management.
Patients who do not respond to high-dose inhaled corticosteroids are often prescribed oral steroids, which carry serious long-term side effects including osteoporosis, diabetes, and immune suppression. If low-dose theophylline could restore steroid sensitivity, it would allow these patients to return to lower, safer steroid doses. The biological rationale is sound and well-characterized in laboratory studies. However, laboratory mechanisms do not always translate into meaningful clinical outcomes — and this is where theophylline’s comeback story hits a wall. The gap between what theophylline does in cell cultures and bronchial biopsies versus what it achieves in large patient populations has proven difficult to bridge. Patients considering this option with their physicians should understand that the mechanistic promise and the clinical reality are, as of 2026, not yet aligned.
The TWICS Trial and What Large-Scale Evidence Actually Shows
The definitive test of the low-dose theophylline hypothesis came in 2018 with the publication of the TWICS trial in JAMA. this was no small study — 1,578 COPD patients were recruited from 121 centers across the United Kingdom and randomized to receive either low-dose theophylline or placebo for one year, alongside their usual inhaled corticosteroid therapy. The primary outcome was the number of COPD exacerbations, which are the acute flare-ups that drive hospitalizations and mortality in this disease. The headline result was disappointing for theophylline advocates. Mean exacerbations were 2.24 in the theophylline group versus 2.23 in the placebo group — a difference so small it was statistically and clinically meaningless.
The drug showed no significant effects on lung function as measured by FEV1, no reduction in pneumonia risk, no improvement in quality of life scores, and no mortality benefit. One secondary finding was intriguing: COPD hospital admissions were 28 percent lower in the theophylline group, with an adjusted incidence rate ratio of 0.72 and a 95 percent confidence interval of 0.55 to 0.94. But as a secondary outcome in a trial that missed its primary endpoint, this finding requires cautious interpretation. The situation worsened with a 2025 systematic review and meta-analysis published in PLOS ONE, which pooled data from multiple trials of theophylline as an add-on to inhaled corticosteroids in COPD. The review found no association between theophylline use and reduced exacerbations, and in some analyses, the theophylline group demonstrated higher hospitalization rates and mortality. These findings prompted The Lancet Respiratory Medicine to publish an editorial bluntly titled “The death of low-dose oral theophylline for COPD?” and the European Respiratory Journal followed with a provocative piece arguing “yes to caffeine, no to theophylline” for COPD management.
Where Theophylline Still Has a Place in Clinical Practice
Despite the negative large-trial results, theophylline has not been entirely abandoned. A 2024 narrative review in the Journal of Thoracic Disease, titled “Is there still a place for an old friend?”, concluded that the drug retains a niche role in difficult-to-treat and refractory cases where standard therapies have failed. Current guidelines from GINA (2024–2025) and a 2023 scoping review from the American College of Clinical Pharmacy both classify theophylline as an “alternative therapy” — not recommended as standard treatment, but not removed from the pharmacopeia either. The distinction between refractory asthma and garden-variety asthma is important here. Most asthma patients are well-controlled on inhaled corticosteroids alone or in combination with long-acting beta-agonists. For these patients, theophylline offers no advantage and only adds risk.
But for the estimated 5 to 10 percent of asthma patients whose disease remains poorly controlled despite maximum standard therapy, options are limited. A 2007 study published in the American Journal of Respiratory and Critical Care Medicine found that in patients not receiving inhaled corticosteroids, adding low-dose theophylline alongside montelukast significantly improved asthma control, symptoms, and lung function. This suggests that the drug’s benefits may depend heavily on which patients receive it and what other medications they are already taking. The tradeoff is straightforward: theophylline requires regular blood monitoring to maintain safe plasma levels, it interacts with numerous other medications, and its narrow therapeutic window means that infections, dietary changes, or new prescriptions can push levels into the toxic range. For a patient whose asthma is well-controlled on an inhaler, these risks make no sense. For a patient who has been hospitalized repeatedly despite aggressive treatment, the calculus changes.
Supply Shortages and the Practical Barriers to Access
Even for patients and physicians who decide theophylline is worth trying, a practical obstacle has emerged: the drug is increasingly hard to find. Theophylline has experienced ongoing supply shortages throughout 2025 and into 2026, a problem rooted in structural issues that have been building for over a decade. Brand-name formulations were discontinued between 2010 and 2018, leaving the market dependent on a handful of generic manufacturers. Rhodes Pharmaceuticals has its 400 mg extended-release tablets on back order with no estimated release date. Glenmark has reported shortages due to manufacturing issues. Lower-strength tablets — 100 mg, 200 mg, and 300 mg — are generally more accessible, but availability varies by pharmacy and region. The underlying economics explain why.
Generic theophylline ER is extremely inexpensive, typically costing $10 to $40 per month at retail pharmacies or as little as $4 to $15 per month through discount programs like GoodRx. Under most Medicare Part D plans, it falls under Tier 1 preferred generic status with copays of $0 to $10. While this affordability is a genuine advantage, particularly in resource-limited settings, it also means profit margins for manufacturers are razor-thin. Few companies are willing to invest in maintaining complex production lines for a drug that generates minimal revenue. This creates a paradox: theophylline’s greatest practical strength — its low cost — is also the root cause of its supply instability. Patients who are stable on the medication can face abrupt disruptions, and switching between different extended-release formulations is not straightforward because bioavailability can vary between manufacturers. Physicians prescribing theophylline in 2026 need to have contingency plans, and patients should be warned that their pharmacy may not always have their specific formulation in stock.
Relevance for Older Adults and Cognitive Health Considerations
For readers of a brain health and dementia care website, theophylline’s story intersects with aging in several important ways. The majority of COPD patients are older adults, and the disease frequently coexists with cognitive decline. Medications that require careful blood level monitoring and carry risks of seizures and arrhythmias at supratherapeutic doses demand close oversight — oversight that may be compromised in patients with cognitive impairment or limited caregiver support. Any older adult on theophylline needs a reliable system for medication management, regular blood draws, and prompt communication with their prescribing physician when other medications change.
There is also a broader point worth noting. Theophylline belongs to the methylxanthine family, which includes caffeine — a compound that has drawn considerable research interest for potential neuroprotective effects. However, theophylline itself has not been studied in rigorous clinical trials for cognitive outcomes, and any extrapolation from caffeine research to theophylline would be speculative. Patients and caregivers should not view theophylline as a brain health intervention.
What Comes Next for Low-Dose Theophylline?
The 2024 narrative review in the Journal of Thoracic Disease framed the central question well: theophylline is an “old friend” with a genuine molecular mechanism of action, but one that has not delivered on its clinical promise in large trials. The scientific community appears to have reached a provisional consensus — the drug is not coming back as a mainstream treatment, but it is not going away either.
Its niche in refractory cases, its usefulness in low-resource healthcare settings where inhaled biologics are unaffordable, and its unique HDAC2 mechanism ensure it will continue to appear in pharmacology textbooks and treatment algorithms for difficult cases. Whether future research can identify the specific patient subgroups who benefit most from low-dose theophylline — perhaps through biomarkers of HDAC2 dysfunction or steroid resistance — remains an open question. Until then, the drug occupies an uncomfortable middle ground: too well-understood to dismiss, too underwhelming in trials to recommend broadly, and too cheap for industry to invest in solving its supply problems.
Conclusion
Theophylline’s story is a useful reminder that a compelling biological mechanism does not guarantee clinical effectiveness. The low-dose anti-inflammatory approach — activating HDAC2, reducing eosinophilic inflammation, potentially restoring steroid responsiveness — is scientifically genuine and well-documented. But the TWICS trial and subsequent meta-analyses have shown that these laboratory findings do not reliably translate into fewer exacerbations or better outcomes in large COPD populations.
Current GINA and ERS/ATS guidelines reflect this evidence by declining to recommend theophylline as standard therapy. For patients and caregivers navigating severe, treatment-resistant respiratory disease, theophylline remains a conversation worth having with a pulmonologist — not as a first-line treatment, but as a potential option when other therapies have fallen short. Its extremely low cost makes it accessible, but ongoing supply shortages and the need for blood level monitoring add practical complexity. Anyone considering this medication should do so under close medical supervision, with realistic expectations about what the current evidence supports and what it does not.
Frequently Asked Questions
Is low-dose theophylline safe for older adults?
Theophylline can be used in older adults, but it requires careful monitoring. The drug has a narrow therapeutic window, and age-related changes in liver function can affect how quickly it is metabolized. Plasma levels must be checked regularly, and the risk of toxicity — including nausea, arrhythmias, and seizures — increases if levels exceed the target range of 5–10 mg/L for anti-inflammatory dosing. Older adults taking multiple medications need particular vigilance because of drug interactions.
Does theophylline help with asthma that is not responding to inhalers?
There is some evidence that it can. A 2007 study found that low-dose theophylline combined with montelukast significantly improved asthma control in patients not on inhaled corticosteroids. However, the 2024–2025 GINA guidelines do not recommend it as standard therapy, and it is typically reserved for difficult-to-treat or refractory cases where other options have been exhausted.
How much does theophylline cost?
Generic theophylline extended-release is one of the least expensive respiratory medications available. Retail prices range from $10 to $40 per month, and discount programs can bring the cost down to $4 to $15 per month. Most Medicare Part D plans cover it as a Tier 1 preferred generic with copays of $0 to $10. However, supply shortages in 2025–2026 may affect availability at some pharmacies.
Why is there a theophylline shortage?
The shortage stems from structural issues in generic drug manufacturing. Few companies produce theophylline because profit margins are extremely low, and the extended-release formulation involves complex production processes. Brand-name versions were discontinued between 2010 and 2018, and the remaining generic manufacturers — including Rhodes Pharmaceuticals and Glenmark — have experienced production delays and back orders.
Can theophylline improve brain health or prevent dementia?
There is no clinical evidence that theophylline has cognitive benefits. While it belongs to the methylxanthine family (which includes caffeine, a compound studied for potential neuroprotective properties), theophylline itself has not been tested in rigorous trials for cognitive outcomes. It should not be taken for brain health purposes.
What is the difference between low-dose and standard-dose theophylline?
Standard bronchodilator dosing targets plasma concentrations of 10–20 mg/L and works primarily by relaxing airway smooth muscle. Low-dose therapy targets 5–10 mg/L and works through a different mechanism — activating the enzyme HDAC2 to suppress inflammatory gene expression. The lower dose carries fewer side effects but, based on current large-trial evidence, has not consistently demonstrated clinical benefits in COPD.
